These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 31836681

  • 1. Histologically Confirmed Diagnostic Efficacy of 18F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer.
    Kroenke M, Wurzer A, Schwamborn K, Ulbrich L, Jooß L, Maurer T, Horn T, Rauscher I, Haller B, Herz M, Wester HJ, Weber WA, Eiber M.
    J Nucl Med; 2020 May; 61(5):710-715. PubMed ID: 31836681
    [Abstract] [Full Text] [Related]

  • 2. 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
    Eiber M, Kroenke M, Wurzer A, Ulbrich L, Jooß L, Maurer T, Horn T, Schiller K, Langbein T, Buschner G, Wester HJ, Weber W.
    J Nucl Med; 2020 May; 61(5):696-701. PubMed ID: 31836682
    [Abstract] [Full Text] [Related]

  • 3. Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology.
    Langbein T, Wang H, Rauscher I, Kroenke M, Knorr K, Wurzer A, Schwamborn K, Maurer T, Horn T, Haller B, Wester HJ, Eiber M.
    J Nucl Med; 2022 Sep; 63(9):1334-1342. PubMed ID: 34992154
    [Abstract] [Full Text] [Related]

  • 4. Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer.
    Oh SW, Wurzer A, Teoh EJ, Oh S, Langbein T, Krönke M, Herz M, Kropf S, Wester HJ, Weber WA, Eiber M.
    J Nucl Med; 2020 May; 61(5):702-709. PubMed ID: 31836686
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study.
    Ilhan H, Kroenke M, Wurzer A, Unterrainer M, Heck M, Belka C, Knorr K, Langbein T, Rauscher I, Schmidt-Hegemann NS, Schiller K, Bartenstein P, Wester HJ, Eiber M.
    J Nucl Med; 2022 Aug; 63(8):1208-1214. PubMed ID: 35273094
    [Abstract] [Full Text] [Related]

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Aug; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 10. Detection efficacy of 18F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
    Rauscher I, Karimzadeh A, Schiller K, Horn T, D'Alessandria C, Franz C, Wörther H, Nguyen N, Combs SE, Weber WA, Eiber M.
    J Nucl Med; 2021 Mar 12; 62(12):1719-26. PubMed ID: 33712531
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
    Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M.
    J Urol; 2016 May 12; 195(5):1436-1443. PubMed ID: 26682756
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
    Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, Wondergem M, Roeleveld TA, Boellaard R, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    Eur J Nucl Med Mol Imaging; 2021 Feb 12; 48(2):509-520. PubMed ID: 32789599
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.
    BJU Int; 2017 Feb 12; 119(2):209-215. PubMed ID: 27207581
    [Abstract] [Full Text] [Related]

  • 20. Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer.
    Malaspina S, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M.
    Eur J Nucl Med Mol Imaging; 2021 Oct 12; 48(11):3723-3731. PubMed ID: 33846844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.